Peptide lifting serums sold in the United States are regulated as cosmetics, not drugs, as long as their marketing claims are cosmetic in nature — meaning they describe a temporary aesthetic effect on appearance rather than a structural or physiological change to the body. The FDA does not pre-approve cosmetics before they go to market, but that does not mean you can sell them without regulatory compliance obligations.
Under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), which took full effect in 2024, brands and their contract manufacturers now have mandatory requirements: the manufacturing facility must be registered with the FDA, each cosmetic product must be listed in the FDA's Cosmetic Product Reporting Portal (CPRP), and the responsible party (typically the brand) must report serious adverse events within 15 business days. These are not optional best practices — they are statutory requirements with enforcement authority.
In practice, your contract manufacturer should already be FDA-registered. If you are the brand owner (the entity whose name and address appears on the label), you are the responsible party and must complete the product listing. CPRP listing requires your product name, the responsible party's contact information, the list of ingredients, and the cosmetic category. It is free to submit and takes about 30 minutes per SKU.
Where founders get into trouble is with claims. Describing a serum as 'lifting' or 'firming' or 'reduces the appearance of wrinkles' is cosmetic language. Saying it 'stimulates collagen production' or 'rebuilds dermal matrix' or 'repairs skin' edges into drug territory and can trigger FDA enforcement action. This distinction is not academic — FDA has issued warning letters to cosmetic brands over structure/function claims on peptide products. Review your label copy and marketing claims against FDA's cosmetic vs. drug guidance before going live.
For EU distribution, a Cosmetic Product Safety Report prepared by a qualified safety assessor is mandatory before placing the product on the EU market. Some peptides (notably those with neuromuscular-inhibiting mechanisms like Syn-Ake) may require additional toxicological substantiation in the safety dossier.
AJ Cosmo Labs connects you with formulators and manufacturers who are already operating inside the MoCRA compliance framework, reducing your regulatory exposure from the start.
Read the full guide on Private Label Peptide Lifting Serum Manufacturer Low MOQ →